XNASMNMD
Market cap522mUSD
Dec 24, Last price
7.12USD
1D
0.63%
1Q
19.54%
IPO
106.51%
Name
Mind Medicine (MindMed) Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
162.77%
Rev. gr., 5y
%
Revenues
0k
Net income
-96m
L+102.56%
CFO
-64m
L+28.37%
Earnings
Feb 26, 2025
Profile
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑08 | 2018‑08 | 2017‑08 | 2016‑08 | 2015‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 93,866 | 69,554 | 96,470 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (93,866) | (69,554) | (96,470) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (9,535) | (1,157) | |||||||
Tax Rate | |||||||||
NOPAT | (93,866) | (60,019) | (95,313) | ||||||
Net income | (95,732) 102.56% | (47,261) -49.20% | (93,036) 172.82% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7,529 | 42,297 | 81,924 | ||||||
BB yield | -5.25% | -62.31% | -14.46% | ||||||
| Debt | |||||||||
Debt current | 72 | ||||||||
Long-term debt | 14,129 | 72 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 32 | 1,184 | 1,930 | ||||||
Net debt | (85,575) | (141,998) | (133,539) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (64,365) | (50,139) | (45,824) | ||||||
CAPEX | |||||||||
Cash from investing activities | (297) | ||||||||
Cash from financing activities | 21,848 | 59,051 | 98,824 | ||||||
FCF | (93,866) | (60,019) | (95,313) | ||||||
| Balance | |||||||||
Cash | 99,704 | 142,142 | 133,539 | ||||||
Long term investments | |||||||||
Excess cash | 99,704 | 142,142 | 133,539 | ||||||
Stockholders' equity | (289,857) | (193,841) | (136,626) | ||||||
Invested Capital | 382,152 | 346,014 | 290,220 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 39,157 | 30,857 | 27,377 | ||||||
Price | 3.66 66.36% | 2.20 -89.37% | 20.70 -54.75% | ||||||
Market cap | 143,316 111.11% | 67,886 -88.02% | 566,706 -30.21% | ||||||
EV | 57,741 | (74,112) | 433,167 | ||||||
EBITDA | (90,704) | (66,374) | (93,854) | ||||||
EV/EBITDA | 1.12 | ||||||||
Interest | 1,495 | 359 | |||||||
Interest/NOPBT | |||||||||